Apoptotic Effects of Melittin on 4T1 Breast Cancer Cell Line is associated with Up Regulation of Mfn1 and Drp1 mRNA Expression

Author:

Moghaddam Farnaz D.1ORCID,Mortazavi Pejman2ORCID,Hamedi Somayeh3,Nabiuni Mohammad4ORCID,Roodbari Nasim H.1ORCID

Affiliation:

1. Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

2. Department of Pathology, Faculty of Specialized Veterinary Science, Science and Research Branch, Islamic Azad University, Tehran, Iran

3. Department of Basic Science, Karaj Branch, Islamic Azad University, Karaj, Iran

4. Department of Cell and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran

Abstract

Background and Purpose: Melittin, as the main ingredient of honeybee venom, that has shown anticancer properties. The present study aimed at investigating the cytotoxic impacts of melittin on 4T1 breast cancer cells. Methods: Hemolytic activity of different concentrations (0.125, 0.25, 0.5, 1, 2, 4, 8μg/ml) of melittin was assayed and then cytotoxicity of selected concentrations of melittin (2, 4, 8, 16, 32, and 64μg/ml), 2 and 4μg/ml of cisplatin and 0.513, 0.295 and 0.123μg/ml of doxorubicin was evaluated on 4T1 cells using MTT assay. We used Morphological evaluation and flow cytometric analysis was used. Real time PCR was also used to determine mRNA expression of Mfn1 and Drp1 genes. Results: All compounds showed anti-proliferative effects on the tumor cell line with different potencies. Melittin had higher cytotoxicity against 4T1 breast cancer cells (IC50= 32μg/ml-72h) and higher hemolytic activity (HD50= 1μg/ml), as compared to cisplatin and doxorubicin. Mellitin at 16 and 32μg/ml showed apoptotic effects on 4T1 cells according to the flow cytometric analysis. The Real time PCR analysis of Drp1 and Mfn1 expression in cells treated with 16μg/ml of melittin revealed an up-regulation in Drp1 and Mfn1 genes mRNA expression in comparison with control group. Treatment with 32μg/ml of melittin was also associated with a rise in mRNA expression of Drp1 and Mfn1 as compared to the control group. Conclusion: The results of this study showed that melittin has anticancer effects on 4T1 cell lines in a dose and time dependent manner and can be a good candidate for further research on breast cancer treatment.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference44 articles.

1. DeSantis C.E.; Lin C.C.; Mariotto A.B.; Siegel R.L.; Stein K.D.; Kramer J.L.; Alteri R.; Robbins A.S.; Jemal A.; Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014,64(4),252-271

2. Fiorica J.V.; Breast cancer screening, mammography, and other modalities. Clin Obstet Gynecol 2016,59(4),688-709

3. Eccles S.A.; Aboagye E.O.; Ali S.; Anderson A.S.; Armes J.; Berditchevski F.; Blaydes J.P.; Brennan K.; Brown N.J.; Bryant H.E.; Bundred N.J.; Burchell J.M.; Campbell A.M.; Carroll J.S.; Clarke R.B.; Coles C.E.; Cook G.J.; Cox A.; Curtin N.J.; Dekker L.V.; Silva I.S.; Duffy S.W.; Easton D.F.; Eccles D.M.; Edwards D.R.; Edwards J.; Evans D.; Fenlon D.F.; Flanagan J.M.; Foster C.; Gallagher W.M.; Garcia-Closas M.; Gee J.M.; Gescher A.J.; Goh V.; Groves A.M.; Harvey A.J.; Harvie M.; Hennessy B.T.; Hiscox S.; Holen I.; Howell S.J.; Howell A.; Hubbard G.; Hulbert-Williams N.; Hunter M.S.; Jasani B.; Jones L.J.; Key T.J.; Kirwan C.C.; Kong A.; Kunkler I.H.; Langdon S.P.; Leach M.O.; Mann D.J.; Marshall J.F.; Martin L.; Martin S.G.; Macdougall J.E.; Miles D.W.; Miller W.R.; Morris J.R.; Moss S.M.; Mullan P.; Natrajan R.; O’Connor J.P.; O’Connor R.; Palmieri C.; Pharoah P.D.; Rakha E.A.; Reed E.; Robinson S.P.; Sahai E.; Saxton J.M.; Schmid P.; Smalley M.J.; Speirs V.; Stein R.; Stingl J.; Streuli C.H.; Tutt A.N.; Velikova G.; Walker R.A.; Watson C.J.; Williams K.J.; Young L.S.; Thompson A.M.; Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res 2013,15(5),R92

4. Arnold M.; Karim-Kos H.E.; Coebergh J.W.; Byrnes G.; Antilla A.; Ferlay J.; Renehan A.G.; Forman D.; Soerjomataram I.; Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer 2015,51(9),1164-1187

5. Colditz G.A.; Bohlke K.; Priorities for the primary prevention of breast cancer. CA Cancer J Clin 2014,64(3),186-194

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3